{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:44:33Z","timestamp":1782920673353,"version":"3.54.5"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"DOI":"10.1007\/s11897-026-00765-w","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:49:59Z","timestamp":1782917399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Cardioprotection to Trial Design: Rethinking Cardiac Safety in Oncology"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7413-8449","authenticated-orcid":false,"given":"Antonio","family":"Iaconelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Scacciavillani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cacioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pecorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Kretzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus S.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"765_CR1","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"key":"765_CR2","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","volume":"118","author":"CG Lenneman","year":"2016","unstructured":"Lenneman CG, Sawyer DB. Cardio-oncology. Circ Res. 2016;118:1008\u201320. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.303633.","journal-title":"Circ Res"},{"key":"765_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","volume":"4","author":"T Omland","year":"2022","unstructured":"Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy cardiotoxicity. JACC CardioOncol. 2022;4:19\u201337. https:\/\/doi.org\/10.1016\/j.jaccao.2022.01.101.","journal-title":"JACC CardioOncol"},{"key":"765_CR4","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jaccao.2025.05.012","volume":"7","author":"R Cagnazzo","year":"2025","unstructured":"Cagnazzo R, Stabile M, Zoppoli G, De Boer RA, Meijers WC, van Der Meer P, et al. Mismatch between preclinical cardio-oncology and clinical oncology research. JACC CardioOncol. 2025;7:770\u20133. https:\/\/doi.org\/10.1016\/j.jaccao.2025.05.012.","journal-title":"JACC CardioOncol"},{"key":"765_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43:280\u201399. https:\/\/doi.org\/10.1093\/eurheartj\/ehab674.","journal-title":"Eur Heart J"},{"key":"765_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pcad.2024.02.002","volume":"85","author":"E D\u00edaz-Balboa","year":"2024","unstructured":"D\u00edaz-Balboa E, Pe\u00f1a-Gil C, Rodr\u00edguez-Romero B, Cuesta-Vargas AI, Lado-Baleato O, Mart\u00ednez-Monzon\u00eds A, et al. Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: the ONCORE randomized controlled trial. Prog Cardiovasc Dis. 2024;85:74\u201381. https:\/\/doi.org\/10.1016\/j.pcad.2024.02.002.","journal-title":"Prog Cardiovasc Dis"},{"key":"765_CR7","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy\u2013induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474\u201381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.635144.","journal-title":"Circulation"},{"key":"765_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3395","volume":"7","author":"L Livi","year":"2021","unstructured":"Livi L, Barletta G, Martella F, Saieva C, Desideri I, Bacci C, et al. Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy. JAMA Oncol. 2021;7:1544. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3395.","journal-title":"JAMA Oncol"},{"key":"765_CR9","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","volume":"148","author":"D Addison","year":"2023","unstructured":"Addison D, Neilan TG, Barac A, Scherrer-Crosbie M, Okwuosa TM, Plana JC, et al. Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the American Heart Association. Circulation. 2023;148:1271\u201386. https:\/\/doi.org\/10.1161\/CIR.0000000000001174.","journal-title":"Circulation"},{"key":"765_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-084062","volume":"390","author":"C Gomes","year":"2025","unstructured":"Gomes C, Geels J, Debray TPA, Malekzadeh A, Asselbergs FW, Linschoten M. Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis. BMJ. 2025;390:e084062. https:\/\/doi.org\/10.1136\/bmj-2025-084062.","journal-title":"BMJ"},{"key":"765_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","volume":"1","author":"M Vaduganathan","year":"2019","unstructured":"Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha VG, et al. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC CardioOncol. 2019;1:54\u201365. https:\/\/doi.org\/10.1016\/j.jaccao.2019.08.006.","journal-title":"JACC CardioOncol"},{"key":"765_CR12","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M, Dom\u00e8nech A, Ortiz-P\u00e9rez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. J Am Coll Cardiol. 2013;61:2355\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.072.","journal-title":"J Am Coll Cardiol"},{"key":"765_CR13","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37:1671\u201380. https:\/\/doi.org\/10.1093\/eurheartj\/ehw022.","journal-title":"Eur Heart J"},{"key":"765_CR14","doi-asserted-by":"publisher","unstructured":"Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2\u00d72 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. Circulation. 2021;143:2431\u201340. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.05469.","DOI":"10.1161\/CIRCULATIONAHA.121.05469"},{"key":"765_CR15","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101\u2013Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol. 2017;35:870\u20137. https:\/\/doi.org\/10.1200\/JCO.2016.68.7830.","journal-title":"J Clin Oncol"},{"key":"765_CR16","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","volume":"71","author":"MS Avila","year":"2018","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, das Dores Cruz F, Goncalves Brandao SM, Rigaud VO, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity. J Am Coll Cardiol. 2018;71:2281\u201390. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.049.","journal-title":"J Am Coll Cardiol"},{"key":"765_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","volume":"94","author":"D Cardinale","year":"2018","unstructured":"Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018;94:126\u201337. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.005.","journal-title":"Eur J Cancer"},{"key":"765_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","volume":"175","author":"F Lynce","year":"2019","unstructured":"Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019;175:595\u2013603. https:\/\/doi.org\/10.1007\/s10549-019-05191-2.","journal-title":"Breast Cancer Res Treat"},{"key":"765_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jcmg.2022.10.010","volume":"16","author":"T Negishi","year":"2023","unstructured":"Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, et al. Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy. JACC Cardiovasc Imaging. 2023;16:269\u201378. https:\/\/doi.org\/10.1016\/j.jcmg.2022.10.010.","journal-title":"JACC Cardiovasc Imaging"},{"key":"765_CR20","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/eurheartj\/ehae574","volume":"45","author":"TH Marwick","year":"2024","unstructured":"Marwick TH, Dewar E, Nolan M, Shirazi M, Dias P, Wright L, et al. Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial. Eur Heart J. 2024;45:4414\u201324. https:\/\/doi.org\/10.1093\/eurheartj\/ehae574.","journal-title":"Eur Heart J"},{"key":"765_CR21","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","volume":"148","author":"PA Henriksen","year":"2023","unstructured":"Henriksen PA, Hall P, MacPherson IR, Joshi SS, Singh T, Maclean M, et al. Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac Troponin I-guided combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to prevent anthracycline cardiotoxicity: The Cardiac CARE Trial. Circulation. 2023;148:1680\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.064274.","journal-title":"Circulation"},{"key":"765_CR22","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jaccao.2024.07.010","volume":"6","author":"D Austin","year":"2024","unstructured":"Austin D, Maier RH, Akhter N, Sayari M, Ogundimu E, Maddox JM, et al. Preventing cardiac damage in patients treated for breast cancer and lymphoma. JACC CardioOncol. 2024;6:684\u201396. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.010.","journal-title":"JACC CardioOncol"},{"key":"765_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/cvr\/cvae266","volume":"121","author":"G Stefanini","year":"2025","unstructured":"Stefanini G, Carlo-Stella C, Cannata F, Chiarito M, Figliozzi S, Novelli L, et al. Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial. Cardiovasc Res. 2025;121:227\u20139. https:\/\/doi.org\/10.1093\/cvr\/cvae266.","journal-title":"Cardiovasc Res"},{"key":"765_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.196","volume":"17","author":"M Akpek","year":"2015","unstructured":"Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17:81\u20139. https:\/\/doi.org\/10.1002\/ejhf.196.","journal-title":"Eur J Heart Fail"},{"key":"765_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/ehjcvp\/pvab033","volume":"7","author":"P Ameri","year":"2021","unstructured":"Ameri P, Bertero E, Maack C, Teerlink JR, Rosano G, Metra M. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment? Eur Heart J Cardiovasc Pharmacother. 2021;7:539\u201346. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab033.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"765_CR26","unstructured":"Marcely Gimenes Bonatto. Effects of Sacubitril\/Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy - SARAH. Am. Hear. Assoc. Sci. Sess. Chicago, IL, Novemb. 18, 2024. 2024."},{"key":"765_CR27","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1161\/CIRCULATIONAHA.125.076616","volume":"152","author":"T Omland","year":"2025","unstructured":"Omland T, Heck SL, Holte E, Lilleaasen AM, Gynnild MN, Fagerland MW, et al. Sacubitril\/Valsartan and prevention of cardiac dysfunction during adjuvant breast cancer therapy: The PRADA II randomized clinical trial. Circulation. 2025;152:1136\u201345. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.076616.","journal-title":"Circulation"},{"key":"765_CR28","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1002\/ehf2.14466","volume":"10","author":"M Tajstra","year":"2023","unstructured":"Tajstra M, Dyrbu\u015b M, Rutkowski T, Sk\u0142adowski K, Sosnowska-Pasiarska B, G\u00f3\u017ad\u017a S, et al. Sacubitril\/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial. ESC Heart Fail. 2023;10:3174\u201383. https:\/\/doi.org\/10.1002\/ehf2.14466.","journal-title":"ESC Heart Fail"},{"key":"765_CR29","doi-asserted-by":"publisher","first-page":"e2564","DOI":"10.1038\/cddis.2016.418","volume":"8","author":"C Henninger","year":"2017","unstructured":"Henninger C, Fritz G. Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers. Cell Death Dis. 2017;8:e2564\u2013e2564. https:\/\/doi.org\/10.1038\/cddis.2016.418.","journal-title":"Cell Death Dis"},{"issue":"9","key":"765_CR30","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200097","volume":"1","author":"WG Hundley","year":"2022","unstructured":"Hundley WG, D\u2019Agostino R, Crotts T, Craver K, Hackney MH, Jordan JH, et al. Statins and left ventricular ejection fraction following Doxorubicin treatment. NEJM Evid. 2022;1(9):EVIDoa2200097.","journal-title":"NEJM Evid"},{"key":"765_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","volume":"9","author":"P Thavendiranathan","year":"2023","unstructured":"Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, et al. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother. 2023;9:515\u201325. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad031.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"765_CR32","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1001\/jama.2023.11887","volume":"330","author":"TG Neilan","year":"2023","unstructured":"Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, et al. Atorvastatin for anthracycline-associated cardiac dysfunction. JAMA. 2023;330:528. https:\/\/doi.org\/10.1001\/jama.2023.11887.","journal-title":"JAMA"},{"key":"765_CR33","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"key":"765_CR34","doi-asserted-by":"publisher","first-page":"100424","DOI":"10.1016\/j.jacadv.2023.100424","volume":"2","author":"AA Kirkham","year":"2023","unstructured":"Kirkham AA, Mackey JR, Thompson RB, Haykowsky MJ, Oudit GY, McNeely M, et al. TITAN Trial: A Randomized Controlled Trial of a Cardiac Rehabilitation Care Model in Breast Cancer. JACC Adv. 2023;2:100424. https:\/\/doi.org\/10.1016\/j.jacadv.2023.100424.","journal-title":"JACC Adv"},{"key":"765_CR35","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1161\/CIRCULATIONAHA.122.062814","volume":"147","author":"SJ Foulkes","year":"2023","unstructured":"Foulkes SJ, Howden EJ, Haykowsky MJ, Antill Y, Salim A, Nightingale SS, et al. Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the BREXIT study. Circulation. 2023;147:532\u201345. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062814.","journal-title":"Circulation"},{"key":"765_CR36","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/JCO.2013.54.5384","volume":"32","author":"J Baselga","year":"2014","unstructured":"Baselga J, Cort\u00e9s J, Im S-A, Clark E, Ross G, Kiermaier A, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32:3753\u201361. https:\/\/doi.org\/10.1200\/JCO.2013.54.5384.","journal-title":"J Clin Oncol"},{"key":"765_CR37","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3816\/CBC.2010.n.065","volume":"10","author":"J Baselga","year":"2010","unstructured":"Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer. 2010;10:489\u201391. https:\/\/doi.org\/10.3816\/CBC.2010.n.065.","journal-title":"Clin Breast Cancer"},{"key":"765_CR38","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1093\/annonc\/mdx406","volume":"28","author":"D Miles","year":"2017","unstructured":"Miles D, Im Y-H, Fung A, Yoo B, Knott A, Heeson S, et al. Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. Ann Oncol. 2017;28:2761\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdx406.","journal-title":"Ann Oncol"},{"key":"765_CR39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","volume":"14","author":"SM Swain","year":"2013","unstructured":"Swain SM, Kim S-B, Cort\u00e9s J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(13)70130-X.","journal-title":"Lancet Oncol"},{"key":"765_CR40","doi-asserted-by":"publisher","unstructured":"Swain SM, Miles D, Kim S-B, Im Y-H, Im S-A, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:519\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(19)30863-.","DOI":"10.1016\/S1470-2045(19)30863-"},{"key":"765_CR41","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7.","journal-title":"Lancet"},{"key":"765_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng A-L, El-Khoueiry AB, Rimassa L, Ryoo B-Y, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1717002.","journal-title":"N Engl J Med"},{"key":"765_CR43","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1207506.","journal-title":"N Engl J Med"},{"key":"765_CR44","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1093\/annonc\/mdt274","volume":"24","author":"J Cort\u00e9s","year":"2013","unstructured":"Cort\u00e9s J, Baselga J, Im Y-H, Im S-A, Pivot X, Ross G, et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol. 2013;24:2630\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdt274.","journal-title":"Ann Oncol"},{"key":"765_CR45","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1413513.","journal-title":"N Engl J Med"},{"key":"765_CR46","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1161\/CIRCULATIONAHA.118.039180","volume":"139","author":"J Bonsu","year":"2019","unstructured":"Bonsu J, Charles L, Guha A, Awan F, Woyach J, Yildiz V, et al. Representation of patients with cardiovascular disease in pivotal cancer clinical trials. Circulation. 2019;139:2594\u20136. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.039180.","journal-title":"Circulation"},{"key":"765_CR47","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37:2768\u2013801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211.","journal-title":"Eur Heart J"},{"key":"765_CR48","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset J-F, Etienne P-L, Rio E, Fran\u00e7ois \u00c9, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(21)00079-6.","journal-title":"Lancet Oncol"},{"key":"765_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3829","volume":"8","author":"T Conroy","year":"2022","unstructured":"Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, et al. Five-year outcomes of FOLFIRINOX vs Gemcitabine as adjuvant therapy for pancreatic cancer. JAMA Oncol. 2022;8:1571. https:\/\/doi.org\/10.1001\/jamaoncol.2022.3829.","journal-title":"JAMA Oncol"},{"key":"765_CR50","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013777.","journal-title":"Circulation"},{"key":"765_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.15256\/joc.2014.4.41","volume":"4","author":"EA Bayliss","year":"2014","unstructured":"Bayliss EA, Reifler LM, Zeng C, McQuillan DB, Ellis JL, Steiner JF. Competing Risks of Cancer Mortality and Cardiovascular Events in Individuals with Multimorbidity. J Comorb. 2014;4:29\u201336.","journal-title":"J Comorb"},{"key":"765_CR52","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaccao.2022.08.002","volume":"4","author":"Y Li","year":"2022","unstructured":"Li Y, Sun L, Burstein DS, Getz KD. Considerations of competing risks analysis in cardio-oncology studies. JACC CardioOncol. 2022;4:287\u2013301. https:\/\/doi.org\/10.1016\/j.jaccao.2022.08.002.","journal-title":"JACC CardioOncol"},{"key":"765_CR53","doi-asserted-by":"publisher","first-page":"1360266","DOI":"10.3389\/fonc.2024.1360266","volume":"14","author":"HT Kim","year":"2024","unstructured":"Kim HT. Competing risks data in clinical oncology. Front Oncol. 2024;14:1360266. https:\/\/doi.org\/10.3389\/fonc.2024.1360266.","journal-title":"Front Oncol"},{"key":"765_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-021-00096-w","volume":"7","author":"L Prior","year":"2021","unstructured":"Prior L, Featherstone H, O\u2019Reilly D, Nugent K, Lim M, McCaffrey J, et al. Competing mortality risks: predicted cardiovascular disease risk versus predicted risk of breast cancer mortality in patients receiving adjuvant chemotherapy in a single Irish center. Cardiooncology. 2021;7:8. https:\/\/doi.org\/10.1186\/s40959-021-00096-w.","journal-title":"Cardiooncology"},{"key":"765_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-024-00292-4","volume":"10","author":"J Lee","year":"2024","unstructured":"Lee J, Tan S, Ramkumar S. Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of Anthracycline cardiotoxicity. Cardiooncology. 2024;10:88. https:\/\/doi.org\/10.1186\/s40959-024-00292-4.","journal-title":"Cardiooncology"},{"key":"765_CR56","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin S, Kudo M, Meyer T, Bai Y, Guo Y, Meng Z, et al. Tislelizumab vs Sorafenib as first-line treatment for unresectable hepatocellular carcinoma. JAMA Oncol. 2023;9:1651. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4003.","journal-title":"JAMA Oncol"},{"key":"765_CR57","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12872-021-01996-6","volume":"21","author":"MF Barbosa","year":"2021","unstructured":"Barbosa MF, Fusco DR, Gaiolla RD, Werys K, Tanni SE, Fernandes RA, et al. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines. BMC Cardiovasc Disord. 2021;21:170. https:\/\/doi.org\/10.1186\/s12872-021-01996-6.","journal-title":"BMC Cardiovasc Disord"},{"key":"765_CR58","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jaccao.2021.09.015","volume":"3","author":"N van der Velde","year":"2021","unstructured":"van der Velde N, Janus CPM, Bowen DJ, Hassing HC, Kardys I, van Leeuwen FE, et al. Detection of subclinical cardiovascular disease by cardiovascular magnetic resonance in lymphoma survivors. JACC: CardioOncology. 2021;3:695\u2013706. https:\/\/doi.org\/10.1016\/j.jaccao.2021.09.015.","journal-title":"JACC: CardioOncology"},{"key":"765_CR59","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamaoncol.2022.5959","volume":"9","author":"M Provencio","year":"2023","unstructured":"Provencio M, Ortega AL, Coves-Sarto J, Calvo V, Mars\u00e9-Fabregat R, D\u00f3mine M, et al. Atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non\u2013small cell lung cancer with high tumor mutation burden. JAMA Oncol. 2023;9:344. https:\/\/doi.org\/10.1001\/jamaoncol.2022.5959.","journal-title":"JAMA Oncol"},{"key":"765_CR60","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1200\/JCO.19.00066","volume":"37","author":"SM Tolaney","year":"2019","unstructured":"Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2019;37:1868\u201375. https:\/\/doi.org\/10.1200\/JCO.19.00066.","journal-title":"J Clin Oncol"},{"key":"765_CR61","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390. https:\/\/doi.org\/10.1056\/NEJMoa0708857.","journal-title":"N Engl J Med"},{"key":"765_CR62","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim S-B, Im S-A, Hegg R, Im Y-H, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1113216.","journal-title":"N Engl J Med"},{"key":"765_CR63","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S1470-2045(15)00159-X","volume":"16","author":"C R\u00f6del","year":"2015","unstructured":"R\u00f6del C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO\/ARO\/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16:979\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(15)00159-X.","journal-title":"Lancet Oncol"},{"key":"765_CR64","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","volume":"13","author":"G Ismael","year":"2012","unstructured":"Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim S-B, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I\u2013III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13:869\u201378. https:\/\/doi.org\/10.1016\/S1470-2045(12)70329-7.","journal-title":"Lancet Oncol"},{"key":"765_CR65","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1470-2045(13)70599-0","volume":"15","author":"J-F Bosset","year":"2014","unstructured":"Bosset J-F, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun R-J, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(13)70599-0.","journal-title":"Lancet Oncol"},{"key":"765_CR66","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S1470-2045(14)70377-8","volume":"15","author":"YS Hong","year":"2014","unstructured":"Hong YS, Nam B-H, Kim K, Kim JE, Park SJ, Park YS, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15:1245\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(14)70377-8.","journal-title":"Lancet Oncol"},{"key":"765_CR67","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu T-E, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198\u2013211. https:\/\/doi.org\/10.1016\/S1470-2045(20)30641-0.","journal-title":"Lancet Oncol"},{"key":"765_CR68","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz H-J, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(17)30422-9.","journal-title":"Lancet Oncol"},{"key":"765_CR69","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"J-M Sun","year":"2021","unstructured":"Sun J-M, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4.","journal-title":"Lancet"},{"key":"765_CR70","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","volume":"24","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Cercek A, Siena S, Andr\u00e9 T, Ng K, Van Cutsem E, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24:496\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(23)00150-X.","journal-title":"Lancet Oncol"},{"key":"765_CR71","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.6797","volume":"11","author":"R Kristeleit","year":"2025","unstructured":"Kristeleit R, Devlin M-J, Clamp A, Gourley C, Roux R, Hall M, et al. Pembrolizumab in patients with advanced clear cell gynecological cancer. JAMA Oncol. 2025;11:377. https:\/\/doi.org\/10.1001\/jamaoncol.2024.6797.","journal-title":"JAMA Oncol"},{"key":"765_CR72","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jamaoncol.2024.5927","volume":"11","author":"K Ramalingam","year":"2025","unstructured":"Ramalingam K, Woody R, Glencer A, Schwartz CJ, Mori H, Wong J, et al. Intratumoral injection of mRNA-2752 and pembrolizumab for high-risk ductal carcinoma in situ: a phase 1 nonrandomized clinical trial. JAMA Oncol. 2025;11:288\u201392. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5927.","journal-title":"JAMA Oncol"},{"key":"765_CR73","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(18)30700-9.","journal-title":"Lancet Oncol"},{"key":"765_CR74","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non\u2013small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41:1992\u20138. https:\/\/doi.org\/10.1200\/JCO.22.01989.","journal-title":"J Clin Oncol"},{"key":"765_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-025-00411-9","volume":"11","author":"A Albulushi","year":"2025","unstructured":"Albulushi A, Al-Farhan H. Bridging gaps in AI-driven cardio-oncology: global advances and Middle East perspectives. Cardiooncology. 2025;11:110. https:\/\/doi.org\/10.1186\/s40959-025-00411-9.","journal-title":"Cardiooncology"},{"key":"765_CR76","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.124.011504","volume":"18","author":"EK Oikonomou","year":"2025","unstructured":"Oikonomou EK, Sangha V, Dhingra LS, Aminorroaya A, Coppi A, Krumholz HM, et al. Artificial intelligence-enhanced risk stratification of cancer therapeutics-related cardiac dysfunction using electrocardiographic images. Circ Cardiovasc Qual Outcomes. 2025;18:e011504. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.124.011504.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"765_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15060787","volume":"15","author":"LC Nechita","year":"2025","unstructured":"Nechita LC, Tutunaru D, Nechita A, Voipan AE, Voipan D, Tupu AE, et al. AI and smart devices in cardio-oncology: Advancements in cardiotoxicity prediction and cardiovascular monitoring. Diagnostics (Basel). 2025;15:787. https:\/\/doi.org\/10.3390\/diagnostics15060787.","journal-title":"Diagnostics (Basel)"},{"key":"765_CR78","doi-asserted-by":"publisher","first-page":"e63964","DOI":"10.2196\/63964","volume":"11","author":"H Mushcab","year":"2025","unstructured":"Mushcab H, Al Ramis M, AlRujaib A, Eskandarani R, Sunbul T, Al Otaibi A, et al. Application of artificial intelligence in cardio-oncology imaging for cancer therapy\u2013related cardiovascular toxicity: A systematic review. JMIR Cancer. 2025;11:e63964\u2013e63964. https:\/\/doi.org\/10.2196\/63964.","journal-title":"JMIR Cancer"},{"key":"765_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2025.06.013","author":"A Lala","year":"2025","unstructured":"Lala A, Beavers C, Blumer V, Brewer L, De Oliveira-Gomes D, Dunbar SB, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and The American Society for Preventive Cardiology. J Card Fail. 2025. https:\/\/doi.org\/10.1016\/j.cardfail.2025.06.013.","journal-title":"J Card Fail"},{"issue":"10","key":"765_CR80","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/ejhf.3799","volume":"27","author":"MS Anker","year":"2025","unstructured":"Anker MS, Mahabadi AA, Totzeck M, Tewes M, Mincu R, Khan MS, et al. Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trial. Eur J Heart Fail. 2025;27(10):1905\u201317. https:\/\/doi.org\/10.1002\/ejhf.3799.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"765_CR81","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/eurheartj\/ehaf705","volume":"47","author":"MS Anker","year":"2025","unstructured":"Anker MS, Mahabadi AA, Totzeck M, Tewes M, Shahzeb Khan M, Mincu RI, et al. Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial). Eur Heart J. 2025;47(9):1034\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf705.","journal-title":"Eur Heart J"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00765-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-026-00765-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00765-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:50:06Z","timestamp":1782917406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-026-00765-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1007\/s11897-026-00765-w","relation":{},"ISSN":["1546-9549"],"issn-type":[{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"29"}}